Researchers Use Nanoparticles to Test Treatment for Liver Disease
June 25, 2018 | Katie Neith
In an effort to improve options for those with liver cancer, a group of researchers have identified a way of potentially treating a broad range of liver diseases and perhaps even other types of cancer.
$2 million grant awarded to City of Hope to promote critical research on aging and cancer
June 1, 2018 | Letisia Marquez
The National Institute of Aging has awarded $2 million to City of Hope to establish a national research infrastructure that will facilitate and support significant innovative projects across the country addressing aging and cancer.
TGen Spotlight: New Study Tackles Sports-Related Concussions
October 16, 2017 | City of Hope
TGen-Riddell partnership results could help future studies lead to advanced methods of injury and disease detection
Leukemia and Autoimmune Disease Targeted in City of Hope-Caltech Collaboration
October 10, 2017 | Wayne Lewis
The Caltech-City of Hope Biomedical Research Initiative combines the strengths of these top Southern California research institutions to accelerate scientific investigations and fight disease.
Behnam Badie given $2.1 million R01 grant to study RAGE
May 3, 2017 | Denise Heady
What started as an unplanned lunch date has turned into a potential breakthrough in the treatment of gliomas – a fast-growing, and often deadly type of brain tumor.
City of Hope Partners with Scripps to Find New Treatment for HIV
May 2, 2017 | Michael Easterling
A team from The Scripps Research Institute (TSRI) in La Jolla, California, is working with City of Hope’s Center for Gene Therapy to test a cell culture resistant to the HIV virus for efficacy and safety. If testing goes as planned, TSRI and City of Hope investigators may have identified a new treatment for HIV.
TGen Identifies Promising New Compound for Treatment of Glioblastoma
April 20, 2017 | City of Hope
A study led by scientists at the Translational Genomics Research Institute (TGen) has identified a chemical compound called Aurintricarboxylic Acid (ATA), shown to block the chemical cascade that otherwise allows glioblastoma cells to resist both chemo and radiation therapy.